

**West Virginia Medicaid PDL  
Recommended Changes Summary  
Pharmacy and Therapeutics Committee Meeting  
April 26th, 2023**



<b>DRUG</b>	<b>CURRENT PDL STATUS</b>	<b>07/01/2023 PLANNED PDL STATUS</b>	<b>RECOMMEND GRANDFATHER EXISTING USERS</b>	<b>COMMENTS</b>
<b>ANTIBIOTICS, VAGINAL</b>				
Xaciato (clindamycin) gel	New to PDL	Non-Preferred		
<b>ANTIPSYCHOTICS, ATYPICAL</b>				
asenapine maleate sublingual tablets	Non-Preferred	Preferred		
Invega (paliperidone) tablets	Preferred	Non-Preferred		
Latuda (lurasidone) tablets	Preferred	Non-Preferred		
lurasidone tablets	New to PDL	Preferred		
paliperidone ER tablets	Non-Preferred	Preferred		
Saphris (asenapine maleate) sublingual tablets	Preferred	Non-Preferred		
<b>ANTIRETROVIRALS</b>				
Sunlenca (lenacapavir) vials and tablets	New to PDL	Non-Preferred		
<b>CYTOKINE &amp; CAM ANTAGONISTS</b>				
Amjevita (adalimumab-atto) auto-injectors and vials	New to PDL	Non-Preferred		
<b>MULTIPLE SCLEROSIS</b>				
Aubagio (teriflunomide) tablets	Preferred	Non-Preferred		
teriflunomide tablets	New to PDL	Preferred		
<b>STIMULANTS AND RELATED AGENTS</b>				
Xelstrym (dextroamphetamine) patches	New to PDL	Non-Preferred		